[摘要] 目的 观察盐酸帕罗西汀联合利维爱治疗围绝经期抑郁症的临床疗效。 方法 选取2016年1月~2017年1月在我院住院治疗的围绝经期抑郁症患者50例,所有患者根据治疗方法不同分为观察组(n=20)和对照组A组(n=15)、对照组B组(n=15),对照组A组予利维爱2.5 mg,每天1次,口服,对照组B组予盐酸帕罗西汀20 mg,每天1次,口服,根据病情逐渐以每周增加10 mg为阶梯递增,治疗剂量范围为20~60 mg/d,分次口服。观察组予盐酸帕罗西汀联合利维爱治疗,用法同上。共干预8周。 结果 观察组患者治疗后的总有效率95.0%,明显高于对照组A组、B组的总有效率,差异具有统计学意义(P /6/view-10121965.htm
[关键词] 围绝经期抑郁症;盐酸帕罗西汀;利维爱;生活质量
[中图分类号] R749.4 [文献标识码] B [文章编号] 1673-9701(2018)06-0102-03
[Abstract] Objective To investigate the clinical effectiveness of treatment combining paroxetine hydrochloride(PRXT) and livial in perimennopausal patients with depressive disorder. Methods 50 perimenopausal patients with depressive disorder in our hospital from January 2016 to January 2017 were selected and divided into observation group(n=20), control group A(n=15) and control group B(n=15) according to different treatments. Patients in control group A were treated with livial 2.5 mg per day by oral administration. Patients in control group B were treated with PRXT 20 mg per day by oral administration. The administration would increase progressively by 10 mg per week based on patient’s conditions, ranging from 20 to 60 mg per day and given separately. Patients in observation group were treated with PRXT and livial by using the same methods of administration in control group. The treatments lasted 8 weeks. Results The total rate of effectiveness of patients in observation group was 95.0%, which was significantly higher than that of control group A and B(P 1 资料与方法
1.1 一般资料
选取2016年1月~2017年1月在我院住院治疗的围绝经期抑郁症患者50例,纳入标准:(1)围绝经期症状评分(改良Kupperman KMI)[2]≥17分;(2)20项汉密尔顿抑郁量表(HAMD)总评分>20分;(3)有症状时间>3个月,闭经时间0.05),具有可比性。见表1。所有入选患者均对本研究知情同意。
1.2治疗方法
对照组A组予利维爱2.5 mg,每天1次,口服;对照组B组予盐酸帕罗西汀(浙江尖峰药业有限公司,规格:20 mg/片)20 mg,每天1次,口服,根据病情逐渐以每周增加10 mg为阶梯递增,治疗剂量范围为20~60 mg/d,分次口服。观察组予盐酸帕罗西汀联合利维爱(默沙东制药,进口药品注册证号:H20120471)治疗,用法同上。共干预8周。
1.3 观察指标
1.3.1 临床疗效评价 以 HAMD 减分率评价疗效,减分率>75%为临床治愈,50%~74%为显效,25%~49%为有效,参考文献]
[1] 吴萍,楼云霞,陈小鸣. 围绝经期抑郁症与性激素水平关系的研究[J]. 中国性科学, 2015,24(3):108-109.
[2] 张孟丽,郑桂英,吴艳军,等.围绝经期抑郁的研究进展[J].中国妇幼保健,2013,28(1):5236-5237.